Related Experiment Video
Updated: May 10, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
An update on transcatheter aortic valve replacement
Insights
Transcatheter aortic valve replacement (TAVR) offers a life-saving option for severe aortic stenosis patients previously denied treatment. TAVR significantly reduces mortality and is noninferior to traditional surgery in high-risk individuals.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Technology
Background:
- Severe symptomatic aortic stenosis historically left inoperable patients with limited options.
- Transcatheter aortic valve replacement (TAVR) has emerged as a significant advancement.
- Over 50,000 TAVRs have been performed globally, primarily in Europe.
Purpose of the Study:
- To evaluate the efficacy and safety of TAVR in patients with severe symptomatic aortic stenosis.
- To compare TAVR outcomes against medical therapy and traditional open-heart surgery.
Main Methods:
- Analysis of short-term results from the Placement of Aortic Transcatheter Valve (PARTNER) I trial.
- Review of long-term European/Canadian registry data for TAVR outcomes.
Main Results:
- TAVR demonstrated a significant reduction in mortality compared to medical therapy alone in inoperable patients (cohort B).
- TAVR proved noninferior to open aortic valve replacement in high-risk operable patients (cohort A).
Conclusions:
- TAVR is a viable and effective treatment for severe symptomatic aortic stenosis, improving survival rates.
- Ongoing technical advancements and operator experience are expanding TAVR's applicability to lower-risk populations.
Abstract:
Before the development of transcatheter aortic valve replacement (TAVR), patients with severe symptomatic aortic stenosis and significant comorbidities who were deemed inoperable were left with no therapeutic option but palliative care. Today, 11 years after Dr Alain Cribier's first transcatheter aortic valve implantation in 2002, more than 50,000 TAVRs have been performed worldwide, majority in Europe. Short-term results from the recently conducted Placement of Aortic Transcatheter Valve (PARTNER) I trial and long-term results from the European/Canadian registry experiences show significant reduction in mortality compared with medical therapy alone (inoperable cohort B) and noninferiority of TAVR versus open aortic valve replacement in high-risk patients (operable high-risk cohort A). Technical advances and increasing operator experience will further decrease procedure-related complications and may make TAVR an alternative to open aortic valve replacement in even younger and low- to medium-risk patients with severe symptomatic calcific aortic valve stenosis.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Aortic Regurgitation I: Introduction
Aortic Regurgitation IV: Nursing Management